RSV Prevention Has Moved From Theory to Routine Care, But Access Still Shapes Impact
Respiratory syncytial virus is no longer a single-product story. It now spans maternal vaccination, infant monoclonal antibodies, vaccines for older adults, and immunisation options for adults at higher risk, with 39 candidates still in clinical development. The field has advanced quickly, yet implementation remains uneven because cost, delivery logistics, and health-system design continue to determine who actually benefits. In practice, the gap is no longer about whether RSV prevention can work. It is about whether health systems can place effective products into the hands of pregnant people, infants, older adults, and patients with medical vulnerability before seasonal circulation drives hospital care.
Severe RSV disease still falls hardest on infants and older adults, the two groups in whom immune immaturity or immune senescence can turn a common respiratory virus into a major clinical event. The preventive toolkit now includes both active and passive immunisation strategies, each with different timing, durability, and delivery requirements. Maternal vaccination depends on antenatal access and transplacental transfer of protection. Infant monoclonal antibodies bypass the need for infant immune priming and can provide immediate protection during the first vulnerable months of life. Older-adult vaccines and products for adults at high risk extend prevention beyond pediatrics, where RSV has long been underestimated as a cause of serious lower respiratory tract disease.
A central message emerges from real-world evidence: efficacy seen in trials is translating into high effectiveness outside the controlled setting. In routine practice, RSV preventive products are performing well against clinically meaningful outcomes, confirming that the biological strategy is sound. This matters because real-world effectiveness is the metric that determines whether a product reduces hospital admissions, severe respiratory illness, and downstream strain on inpatient services once it enters ordinary clinical care. When a preventive intervention retains strong performance after deployment, the bottleneck shifts away from drug activity and toward access, timing, and uptake.
High effectiveness has not removed the problem of uneven reach.
Cost remains a major barrier, and implementation has largely been limited to higher-income settings. That constraint creates an uncomfortable mismatch between where RSV causes severe disease and where preventive products are actually available. A health system can have a clinically strong intervention on paper and still fail to produce population-level benefit if reimbursement, procurement, cold-chain logistics, antenatal workflows, or pharmacy access make the intervention difficult to deliver at scale. In that sense, RSV prevention now sits at a familiar inflection point: a powerful biomedical advance awaiting the infrastructure needed to turn product approval into public health impact.
The review also points to an important and somewhat underappreciated development: benefits beyond respiratory disease. Emerging real-world data suggest reduced cardiovascular events in older adults receiving RSV prevention. For clinicians, the biological plausibility is straightforward. Acute viral respiratory infections can destabilize vulnerable cardiovascular physiology through systemic inflammation, increased metabolic stress, hypoxemia, and plaque vulnerability. If RSV prevention lowers infection incidence or disease severity, it may also blunt those downstream cardiovascular triggers. The finding broadens the clinical conversation from “prevent pneumonia and bronchiolitis” to a more integrated view of infection prevention as a way to reduce cardiopulmonary decompensation in older adults.
Different preventive products appear similarly effective, but uptake is not similar. Maternal vaccination and monoclonal antibodies can deliver comparable protection, yet their real-world deployment diverges because health systems do not deliver them through identical pathways. Maternal vaccination depends on antenatal care engagement, counseling, and vaccination access during pregnancy. Infant monoclonal antibodies require postnatal systems that can identify eligible infants and administer prophylaxis at the right time. Both strategies can be clinically effective, but the pathway to each one is shaped by different friction points in routine care. Product availability alone cannot correct those structural differences.
Uptake Depends on Familiar Care Pathways, Not Just Regulatory Approval
Communication sits near the center of this problem. Trustworthy provider recommendation can determine whether a preventive product reaches the patient at the right moment, particularly when the intervention is new, seasonally timed, or unfamiliar to families and clinicians. Integration into accessible routine care also matters because prevention delivered outside standard workflows is easy to miss. In pregnancy care, that may mean aligning vaccination with antenatal visits. In pediatrics, it may mean embedding monoclonal antibody delivery into well-child systems or seasonal readiness protocols. For older adults, it may depend on primary care, pharmacy, and long-term care delivery models that can absorb another preventive intervention without adding unnecessary friction.
The review’s practical relevance lies in this combination of effectiveness and implementation reality. RSV prevention is not limited by scientific uncertainty alone. The evidence base now supports a broad preventive approach across age groups, but public health effect will depend on whether countries and health systems can convert biologic success into consistent, equitable delivery. When preventive products are expensive, uptake lags behind approval. When uptake lags, the burden of RSV remains concentrated in the very groups these interventions were designed to protect.
The review also reflects a field in motion. Thirty-nine candidates remain in development, even as one promising pediatric live-attenuated vaccine candidate has been discontinued. Development setbacks have not slowed the broader momentum, but they do reinforce a basic truth in infectious diseases: not every promising vaccine pathway survives contact with clinical development, and not every approved product reaches the people who need it most. That creates a two-front challenge for RSV prevention—continued innovation on one side and far better delivery on the other.
Clinical practice now has multiple tools for RSV prevention, and the near-term question is not whether the tools work. It is how to place them into routine care in a way that reaches infants, pregnant people, older adults, and medically vulnerable patients before seasonal disease begins. The limiting step is no longer immunology. It is implementation, affordability, and the quality of the communication that turns recommendation into acceptance.